EHA 2023 | The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian
• 13 Jun 2023
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shares some highlights from a session on molecular testing in patients with myeloproliferative neoplasms (MPNs), discussing which patient subgroups can benefit from routine JAK2 variant allele frequency (VAF) testing and highlighting the benefits of quantifying JAK2 allelic burden at diagnosis and during follow-up. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
